Background: Definitive antifungal therapy is typically based on Candida species and clinical status, rather than susceptibility reports. Antifungal susceptibility testing is available, but the impact on treatment decisions is unknown. The purpose of this study was to assess antifungal therapy in hospitalized patients with candidaemia during the time period between the start of empirical therapy and after antifungal susceptibility testing reports are available.
Introduction
Candida species are responsible for 8%-10% of all bloodstream infections and are the most common cause of fungal bloodstream infections in hospitalized patients. 1, 2 Antifungal susceptibility varies among Candida species. Candida albicans, Candida tropicalis and Candida parapsilosis are generally susceptible to fluconazole, while Candida glabrata are generally susceptible dose-dependent or resistant to fluconazole. Candida krusei are usually intrinsically resistant to fluconazole. The CLSI Antifungal Testing Subcommittee has established breakpoints for fluconazole; MICs of ≤8 mg/L, 16 -32 mg/L and .32 mg/L are defined as susceptible, susceptible dose-dependent and resistant, respectively. 3, 4 For echinocandin antifungals, formal breakpoints have not been established by the CLSI; however, the CLSI has provided a consensus statement that species with an echinocandin MIC of ≤2 mg/L are susceptible. This is applicable to all three echinocandins (caspofungin, micafungin and anidulafungin). 5 The 2009 Infectious Diseases Society of America (IDSA) guidelines recommend fluconazole or an echinocandin as initial, empirical treatment for non-neutropenic patients with candidaemia. 3 Furthermore, an echinocandin is recommended for patients with moderate to severe illness or recent azole exposure. Traditionally, changes to empirical antifungal therapy are based on the type of Candida species and a patient's clinical status. Antifungal susceptibility can potentially help guide treatment decisions to change and optimize empirical antifungal therapy, including de-escalation to fluconazole. Unlike antibiotic susceptibility testing for bacteria, antifungal susceptibility testing is not routinely performed at all institutions due to various reasons, including the delay in obtaining results and costs. 6, 7 However, antifungal susceptibility testing can identify patients with resistant Candida species that are receiving an inappropriate agent and patients who would be candidates for de-escalation to fluconazole. Since 2006, all bloodstream Candida isolates have had susceptibility testing performed at our hospital. However, how clinicians used the antifungal susceptibility testing results to help guide treatment decisions was unknown. The purpose of this study was to assess empirical and definitive antifungal therapy in hospitalized patients with candidaemia before and after an antifungal susceptibility testing report was available to prescribing clinicians. The three specific aims of this study were to describe changes in antifungal therapy during the treatment course based on initial therapy with either fluconazole or an echinocandin, to evaluate treatment patterns based on the antifungal susceptibility of patients receiving fluconazole or an echinocandin just prior to a susceptibility report, and to assess de-escalation to fluconazole in patients with fluconazole-susceptible candidaemia once antifungal susceptibility testing was reported.
Methods

Study design, study period and location
This was a retrospective study of hospitalized patients with bloodstream infections due to Candida species (candidaemia) from June 2006 to December 2009. The study was conducted at St Luke's Episcopal Hospital (SLEH), a large, university-affiliated medical centre in the Texas Medical Center, Houston, TX, USA. Hospitalized, adult patients with their first occurrence of candidaemia that received either fluconazole or an echinocandin were included in the study. Exclusion criteria included patients with relapse, recurrence or breakthrough candidaemia, treatment with an amphotericin-based product or other azoles, or incomplete data. This study was approved by the Institutional Review Board at SLEH and the University of Houston.
Data collection
Data collected using the online medical chart included demographics and microbiological data including date of blood sample collection, date positive, date of final susceptibility report, Candida species, in vitro susceptibility results, and information regarding antifungal therapy. Recent antifungal exposure was defined as any dose of an antifungal received during the same hospital admission as the candidaemia episode but prior to the day the blood culture was collected. The parameters needed to calculate APACHE II scores were obtained from online medical charts and scanned paper charts.
Antifungal susceptibility testing and related definitions
At SLEH, antifungal susceptibility is determined for all bloodstream Candida isolates using Vitek 2. Day collected is defined as the day the initial Candida blood sample is obtained from the patient; day positive is defined as the day the blood cultures turn positive for yeast. On the day positive, the patient's attending physician or infectious diseases consulting physician is informed of the positive culture via telephone. The final susceptibility report day is defined as the day of identification of Candida species and susceptibility results. These results are posted on the patient's online medical chart. In this study, antifungal therapy was categorized based on the time period of initiation. The first antifungal started on or after the day collected was defined as the initial therapy. Empirical therapy was defined as any antifungal initiated on or after the day collected but before identification of the organism. Definitive therapy was defined as antifungal therapy started on or after the final susceptibility report day. Patients with fluconazole-susceptible candidaemia were defined as those with Candida isolates with MICs of ≤8 mg/L. Patients with fluconazole-resistant candidaemia were defined as those with Candida isolates that were either susceptible dosedependent or resistant to fluconazole (MICs of ≥16 mg/L). 3 
Stratification and analysis
Patients' baseline characteristics and changes in antifungal therapy during their treatment course were stratified by fluconazole or an echinocandin as initial therapy. Treatment patterns were evaluated based on therapy with fluconazole or an echinocandin just prior to and after the susceptibility report. Patients with fluconazole-susceptible candidaemia were assessed for de-escalation to fluconazole once antifungal susceptibility testing was reported. Patients were stratified by APACHE II score ,15 or ≥15, calculated for each patient on the day collected. Patients were also stratified based on location in the intensive care unit (ICU) versus non-ICU and candidaemia with C. albicans versus Candida non-albicans.
Data were input in a spreadsheet format (Microsoft w Excel 2007) and stored using a relational database (Microsoft w Access 2007). Stata/IC 11 or SAS version 9.1 was used for analysis. The x 2 test was used for categorical data and Student's t-test was utilized for continuous variables. A P value of ,0.05 was considered statistically significant.
Results
Patients and Candida species
A total of 328 patients with candidaemia were evaluated. One hundred and sixty-one patients met the inclusion criteria, of whom 58 (36%) were initiated on fluconazole and 103 (64%) were initiated on an echinocandin. There was no statistically significant difference in baseline characteristics between fluconazole-initiated and echinocandin-initiated patients (Table 1) . One-hundred and thirty (81%) patients had fluconazolesusceptible candidaemia, while 31 (19%) had fluconazole-resistant candidaemia (19%). The most common Candida species were C. albicans (50%), C. glabrata (19%), C. parapsilosis (13%) and C. tropicalis (12%) ( Table 2 ). Most of the C. albicans (97.5%), 42% of C. glabrata and 90% of both C. parapsilosis and C. tropicalis were susceptible to fluconazole. None of the seven C. krusei isolates was susceptible to fluconazole. One-hundred and sixty (99.4%) Candida isolates were susceptible to caspofungin.
Time to initiation of antifungal therapy
The mean number of days from the day collected to the day positive was 2+1 days and from the day positive to the final susceptibility report day was 3+1 days. Therefore, susceptibility was reported on average 5+2 days after the day collected. Twenty-one (13%) of the 161 patients were initiated on an antifungal on the day collected, 31 (19%) were initiated between the day collected and the day positive, and 80 patients (50%) were Changes in antifungal therapy after initial therapy but before susceptibility report Of patients initiated on fluconazole (n¼ 58), 38 (66%) continued to receive fluconazole, while 20 (34%) were switched to an echinocandin prior to the final susceptibility report day. Of patients initiated on an echinocandin (n¼ 103), 89 (86%) continued to receive an echinocandin, while 14 (14%) were switched to fluconazole prior to the final susceptibility report day.
Changes in antifungal therapy after susceptibility report
Immediately prior to the final susceptibility report day, 52 patients (32%) were on fluconazole and 109 patients (68%) were on an echinocandin. Out of the 52 fluconazole-treated patients, 41 (79%) had candidaemia with fluconazolesusceptible Candida species. Thirty-four of 41 (83%) continued on fluconazole as definitive therapy and 7 of 41 (17%) were switched to an echinocandin. Eleven of 52 (21%) fluconazoletreated patients had candidaemia with fluconazole-resistant Candida species. Seven of these patients were switched to an echinocandin, three were transferred to a long-term care facility or a nursing home prior to the susceptibility report and one continued on fluconazole until discharge from hospital.
Of the 109 echinocandin-treated patients (68%) just prior to susceptibility, 89 had fluconazole-susceptible candidaemia and 20 had fluconazole-resistant isolates. All 20 patients with candidaemia resistant to fluconazole were continued on an echinocandin. Thirty-five of 89 (39%) echinocandin-treated patients with fluconazole-susceptible candidaemia were switched to fluconazole.
De-escalation to fluconazole stratified by severity of illness, hospital location and Candida species An association between de-escalation to fluconazole and initial severity of illness measured using the APACHE II score, hospital location (ICU versus non-ICU) and type of Candida species (C. albicans versus C. non-albicans) in patients with fluconazolesusceptible isolates was assessed (Table 3) . Patients with an APACHE II score of ,15 and isolation of C. albicans were associated with an increased likelihood of de-escalation to fluconazole (P,0.05, each). Twenty-four percent of patients with fluconazole-susceptible, C. non-albicans isolates were de-escalated to fluconazole.
Discussion
It is essential to appropriately treat patients with candidaemia, and to ensure proper and optimal utilization of antifungal agents. 8 -10 The transition from empirical to definitive antifungal therapy is traditionally guided by Candida species and clinical status. Although routinely done with bacterial species, antifungal susceptibility testing is not common in hospitals. At our hospital, routine antifungal susceptibility testing has been performed since 2006 and, thus, we undertook this study to determine how clinicians were using antifungal susceptibility testing data. The strengths of the study include the large sample of patients with their first occurrence of candidaemia, which eliminates possible differences in susceptibility patterns due to a prior treatment course. Furthermore, patients treated with amphotericinbased products and other azoles were excluded to only evaluate patients that were initially treated with fluconazole or an echinocandin as recommended by the IDSA guidelines. 3 Several important observations were made in this study, including the time to conducted a larger, prospective study of 119 patients to evaluate the role of real-time antifungal susceptibility testing in the resolution of infection and all-cause mortality in patients with candidaemia. Clinical outcomes were relatively poor for patients with fluconazole non-susceptible Candida isolates compared with patients with fluconazole-susceptible Candida isolates. Antifungal susceptibility testing was utilized in 12% of patients to change therapy.
In our study, the time from the day of collection to the identification of yeast averaged just over 2 days. The final species identification and susceptibility report averaged an additional 3 days. This delay in identification was reflected in the time to the initiation of antifungal therapy. Thirteen percent of patients were initiated on an antifungal on the day collected. Nineteen percent of patients were initiated on an antifungal between the day collected and the day positive. Fifty percent of patients were initiated on an antifungal once alerted by the clinical microbiology laboratory that blood cultures were positive for yeast. However, 18% were started ≥1 day after the identification of yeast in the blood. This was a concerning finding, as previous studies have shown that delaying antifungal therapy can increase mortality rates. 9, 13 It is evident that antifungal susceptibility testing is not timely enough to assist in improving the time to initiation of antifungals. Rapid diagnostic techniques along with clinical risk indexes to quickly identify patients with Figure 1 . Time to initiation of antifungal therapy. Twenty-one patients (13%) were initiated on an antifungal on the day the blood culture was collected (day collected). Thirty-one patients (19%) were initiated between the day collected and the day the blood culture grew yeast (day positive). The average time (days, mean+SD) from the day collected to the day positive was 2.1+1.1 days. Eighty patients (50%) were initiated on an antifungal on the day positive. Another 29 patients (18%) were initiated 1-4 days after the day positive. Antifungal susceptibility testing 2149 JAC candidaemia will be required to improve the time to initiation of antifungal therapy. 14, 15 During the time period between the start of empirical therapy and the time to susceptibility reports, 34 of 161 (21%) patients were switched to another therapy. Despite this, 11 of 52 (21%) patients with fluconazole-resistant Candida species were being treated with fluconazole immediately prior to the susceptibility reports. This provides strong evidence for the utility of susceptibility testing, as a number of patients with fluconazole-resistant Candida species were receiving inappropriate therapy (i.e. fluconazole) days after the original culture date. As species identification and antifungal susceptibility are generally available at the same time, whether patients with resistant Candida species receiving an inappropriate agent would be identified simply by species identification is unknown. However, as resistant isolates were noted for species traditionally susceptible to fluconazole (C. albicans, C. tropicalis and C. parapsilosis), the likelihood of identifying resistant isolates simply by species would be challenging. In addition, the benefit of changing patients to susceptible antifungal therapy at this late time period will require further study.
Lastly, it is noteworthy that the majority of patients with fluconazole-susceptible isolates (61%) were not de-escalated from an echinocandin to fluconazole. Patients with less severe disease or C. albicans were more likely to be de-escalated. However, even in these groups, the likelihood of de-escalation was 50%. There are several explanations for this finding. There may have been concerns regarding drug -drug interactions with fluconazole and the administration of concomitant medications such as amiodarone, warfarin, dofetilide and immunosuppressants such as tacrolimus, sirolimus and cyclosporine. Clinicians may have missed updates to the culture status, including the susceptibility report, posted online, as these updates are not readily flagged and clinical teams are not directly alerted. However, the majority of patients with fluconazole-resistant isolates had their treatment changed immediately upon identification by the susceptibility report, making this less likely. Due to the delay in susceptibility reports, clinicians may have also decided to complete the duration of therapy with an echinocandin, especially in those who were unable to tolerate oral fluconazole. This was difficult to determine in this retrospective study and will require further study. Finally, due to the lack of clinical data on the use of antifungal susceptibility testing, it is possible that clinicians are not comfortable de-escalating therapy based on these results. Further outcome studies on the importance of antifungal susceptibility testing would be helpful.
Our study has several limitations. This was a single-centre study and the results may not be generalizable to other medical centres. However, as antifungal susceptibility testing is not routinely performed, these results may have benefit for hospitals that are initiating the use of antifungal susceptibility testing. Although we identified associations between de-escalation to fluconazole and clinical variables, specific reasons why some patients were de-escalated and others were not was indeterminate due to retrospective data entry for this study. We can generalize that the clinical judgment of the treating physician impacted the decision to de-escalate to fluconazole. Despite these limitations, we observed that a number of patients were on inappropriate antifungal therapy on the day of susceptibility reports and the majority of patients with susceptible isolates were not de-escalated to a lesser-spectrum, cheaper antifungal. Antimicrobial stewardship programmes could use antifungal susceptibility reports to identify patients potentially in need of clinical intervention. The reporting of antifungal susceptibility patterns by the creation of an antifungiogram similar to the commonly constructed antibiogram may also help improve empirical antifungal therapy.
Using antifungal susceptibility testing, patients with candidaemia given fluconazole with fluconazole-resistant Candida species were identified. Less than 40% of echinocandin-treated patients with fluconazole-susceptible organisms were de-escalated to fluconazole. Antifungal susceptibility testing may help to identify patients in need of clinical intervention. Potential de-escalation to fluconazde calculated by the number of patients given an echinocandin with fluconazole-susceptible Candida species in each category. Actual represents the number of patients that were de-escalated in each category.
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